The Secretary for the Civil Service Patrick Nip Tak-kuen, said that the supplier reported the investigation results to the Department of Health today. It has reported that there are no quality and safety issues.

A new batch of about 300,000 doses of vaccine is expected to be delivered to Hong Kong tomorrow.

On the morning of March 24, packaging defects in 57 injection vials led to the suspension of Fosun-made vaccines.

Shanghai Fosun Pharma had been granted the right by Germany's BioNTech to manufacture and market the mRNA vaccine in mainland China, Hong Kong, Macau and Taiwan.

Elsewhere the vaccine is marketed by Pfizer Inc.